Clinical trial NCT01093105: An Observational Study of Pediatric Subjects With Globoid Cell Leukodystrophy (GLD)
Official title: A Multicenter, Prospective, Longitudinal, Observational Study of Pediatric Subjects With Globoid Cell Leukodystrophy (Krabbe Disease)
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Leukodystrophy, Globoid Cell
Keywords: Leukodystrophy, Globoid Cell
Classic Globoid Cell Leukodystrophy
Early-Onset Globoid Cell Leukodystrophy
Globoid Cell Leukodystrophy
Globoid Cell Leukoencephalopathy
Infantile Globoid Cell Leukodystrophy
Late-Onset Globoid Cell Leukodystrophy
Leukodystrophy, Globoid Cell, Classic
Leukodystrophy, Globoid Cell, Early-Onset
Leukodystrophy, Globoid Cell, Infantile
Leukodystrophy, Globoid Cell, Late-Onset
Psychosine
galactosylsphingosine (psychosine) beta-galactosidase
Psychosine-UDP galactosyltransferase
Krabbe Disease
Krabbe Leukodystrophy
Krabbe's Disease
Krabbe's Leukodystrophy
Lead sponsor: Takeda
Sponsor class: INDUSTRY
Collaborators: name: PharmaNet
name: Nextrials, Inc.
First posted: 2010-03-25
Enrollment: 0
Sex: ALL
Maximum age (years): 21
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects with a documented diagnosis of GLD and clinical signs and symptoms consistent with that diagnosis

Brief summary: The objective of this study is to evaluate the natural history of disease progression in infants with globoid cell leukodystrophy (GLD).

Detailed description: This study is being conducted to gather prospective data on disease progression in infants diagnosed with GLD. This study will be performed using protocol-defined, standardized assessments including clinical, developmental, and neurologic measures. All study visits will be conducted in the subject's home. No travel to the study site is necessary.

Eligibility criteria: Inclusion Criteria:

Subjects must meet all of the following criteria to be considered eligible for this study:

1. The subject has a documented diagnosis of GLD as evidenced by GALC enzyme activity or a GALC genotype that is predictive of GLD.
2. The subject must have clinical signs and symptoms consistent with the diagnosis of infantile GLD including at least 2 of the following:

   1. Chronic difficulty with feeding or unexplained irritability or "fisting" or other signs of abnormal increased tone
   2. CT or MRI imaging, if performed during diagnostic evaluation prior to enrollment, consistent with GLD
   3. Failure to meet at least 2 age-specific developmental milestones consistent with GLD
   4. Loss of deep tendon reflexes or abnormal visual fixation or optic atrophy
3. The subject has documented onset of signs and symptoms consistent with GLD at \<12 months of age and is \<21 months of age at time of study entry.
4. The subject was born at a gestational age of 35-41 weeks.
5. The subject had a birth weight of ≥2 kg.
6. At study entry, the subject must be able to maintain oral nutrition and hydration without the use of supportive measures, defined as use of a feeding tube.
7. At study entry, the subject must be able to maintain ventilation without the use of invasive supportive measures, defined as use of a breathing tube.
8. The subject must be able, in the opinion of the Investigator, to accommodate the protocol requirements, including feasibility of study visits.
9. The subject's parent(s) or legal guardian must have voluntarily signed an Institutional Review Board/Independent Ethics Committee-approved informed consent form after all relevant aspects of the study have been explained and discussed with the subject's parent(s), or legal guardian.

Exclusion Criteria: Subjects who meet any of the following criteria are not eligible for this study:

1. The subject has neurologic, hearing or vision impairment, difficulty swallowing or feeding, respiratory complications, behavioral disturbances, or other medical conditions that are not due to GLD and are likely to confound the scientific integrity or interpretation of study assessments, as determined by the Investigator.
2. The subject has received treatment with any investigational drug or a device within the 30 days prior to study enrollment through study completion.
3. The subject has received a cord blood or bone marrow transplant or is planning to receive one during the study.
4. The subject's parent(s) or legal guardian is unable to understand the nature, scope, and possible consequences of the study, or does not agree to comply with the protocol defined schedule of assessments.

Primary outcomes:
measure: To measure the change from baseline in growth parameters (eg, weight gain, linear growth, head circumference).
timeFrame: 1 year
measure: To determine the onset date of inadequate oral nutrition, hydration, and/or ventilation as a biomarker for survival
timeFrame: 1 year
Secondary outcomes:
measure: To assess the change from baseline in clinical parameters of GLD disease progression from a standardized infant neurological examination and infant distress scales.
timeFrame: 1 year
measure: To assess the change from baseline in clinical parameters described in Hagberg's clinical staging.
timeFrame: 1 year
measure: To measure the time to absolute survival
timeFrame: 1 year
measure: To assess the AE experience in this patient population
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
affiliation: Takeda
name: Study Director
role: STUDY_DIRECTOR
References: